{"id":5493,"date":"2019-07-18T15:53:52","date_gmt":"2019-07-18T10:23:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5493"},"modified":"2021-07-24T12:57:27","modified_gmt":"2021-07-24T07:27:27","slug":"recent-pharma-happenings-for-orum-sosei-puretech","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech","title":{"rendered":"PureHealth acquires LYT-100; Sosei raises USD 2.5 M"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>PureHealth acquires LYT-100 to treat lymphedema<\/strong><\/h4>\n\n\n\n<p>PureTech Health, a pioneer in the development of therapies for dysfunctions in the brain-immune-gut axis, has announced to acquire a clinical-stage drug, <strong>LYT-100<\/strong> for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema. The candidate, LYT-100, is an oral, small molecule, has been acquired from a pharma company where it was under clinical trials for other indication. The candidate exhibited anti-fibrotic and anti-inflammatory mechanisms and was well tolerated in preclinical studies, with a favourable pharmacokinetic profile to support twice-daily oral dosing. With the acquisition of the drug, PureTech plans to expand and progress its R&amp;D pipeline advancing the pipeline for the disorders related to the lymphatic system and local modulation of the immune system such as immune and <strong>central nervous system disorders, lymphatic conditions, and cancers.<\/strong><br><strong>Lymphedema <\/strong>is the most common and chronic lymphatic disease resulting in inflammation, swelling, and build-up of fluid in arms and legs. The most prevalent form of this condition, <strong>secondary lymphedema<\/strong> is usually caused as the side effect of cancer treatments or due to the infections from damages or removal of lymph nodes. At present, the lymphedema treatments comprise compression and physical therapy, with non-curative approaches that fail to correct immune cell infiltration or regenerate the dysregulated lymphatics. However, companies like PureTech Health are committed to developing an effective approach to treat secondary lymphedema without surgery.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Sosei Heptares raises USD 2.5 M, plans to advance its R&amp;D pipeline<\/strong><\/h4>\n\n\n\n<p><strong>Sosei Heptares<\/strong>, a Japan\u2019s biotech pharma company, has secured <strong>USD 2.5 Million<\/strong> in a deal with Formosa Pharmaceuticals, which recently has won FDA approval for its Investigational New Drug (&#8220;IND&#8221;) application for <strong>APP13007<\/strong> to begin a first-in-human (&#8220;FIH&#8221;) clinical trial in the United States. Initially, APP13007 was under the regulation of Activus Pharma, which was divested to form Formosa Pharmaceuticals, as a part of Sosei Heptares\u2019 redirected growth tactic to advance the development of new medicines from its GPCR-targeted StaR technology and structure-based drug design platform capabilities. APP13007 is a nanoparticle formulation of the corticosteroid clobetasol under development for the treatment of post-operative inflammation of the eye.<br><strong>Sosei Heptares<\/strong> is exploring and inking deals with a long list of major pharma giants to accelerate its pipeline. After Allergan, AstraZeneca and Daiichi Sankyo, recently <strong>Sosei collaborated with Genentech,<\/strong> a member of the Roche Group, to discover and develop novel medicines that modulate<strong> G protein-coupled receptor <\/strong>(GPCR) targets across various diseases. The multi-target research collaboration and license agreement are finalised with an upfront payment of USD 26 Million to Sosei and select global rights to Genentech for developing and commercializing potential new medicines.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Orum Therapeutics bags USD 30 M, plans to target undruggable targets <\/strong><\/h4>\n\n\n\n<p><strong>Orum Therapeutics <\/strong>has successfully secured <strong>USD 30 Million <\/strong>in Series B financing led by IMM Investment, Smilegate Investment, KTB Network, and Stassets Investment, join along with the existing ones, InterVest and KB Investment\/Solidus Investment. Orum plans to use the proceeds to fuel its <strong>OromabTM<\/strong>, Orum\u2019s proprietary cell-specific, cell-penetrating antibody platform technology. The Oromab platform has the potential to block RAS activity, thus safely targeting the mutation, and is developed to target novel therapeutics to target cancer and other rare diseases. Orum also plans to expand its R&amp;D labs in Korea and Boston, where the company was lately acknowledged as a biotech incubator in Kendall Square, Cambridge.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PureHealth acquires LYT-100 to treat lymphedema PureTech Health, a pioneer in the development of therapies for dysfunctions in the brain-immune-gut axis, has announced to acquire a clinical-stage drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema. The candidate, LYT-100, is an oral, small molecule, has been acquired from a pharma company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5496,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17740,2003],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-5493","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-purehealth","tag-sosei","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PureHealth acquires LYT-100; Sosei raises $2.5M; Orum secured $30M<\/title>\n<meta name=\"description\" content=\"PureTech Health has announced to acquire a drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PureHealth acquires LYT-100; Sosei raises $2.5M; Orum secured $30M\" \/>\n<meta property=\"og:description\" content=\"PureTech Health has announced to acquire a drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-18T10:23:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2168\" \/>\n\t<meta property=\"og:image:height\" content=\"1185\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PureHealth acquires LYT-100; Sosei raises $2.5M; Orum secured $30M","description":"PureTech Health has announced to acquire a drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech","og_locale":"en_US","og_type":"article","og_title":"PureHealth acquires LYT-100; Sosei raises $2.5M; Orum secured $30M","og_description":"PureTech Health has announced to acquire a drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-18T10:23:52+00:00","article_modified_time":"2021-07-24T07:27:27+00:00","og_image":[{"width":2168,"height":1185,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech","name":"PureHealth acquires LYT-100; Sosei raises $2.5M; Orum secured $30M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1.png","datePublished":"2019-07-18T10:23:52+00:00","dateModified":"2021-07-24T07:27:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"PureTech Health has announced to acquire a drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-orum-sosei-puretech#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1.png","width":2168,"height":1185,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/18214457\/Business-1-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PureHealth<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sosei<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">PureHealth<\/span>","<span class=\"advgb-post-tax-term\">Sosei<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 18, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 18, 2019 3:53 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5493"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5493\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5496"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5493"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5493"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}